Drug Profile
JNJ 61187191
Alternative Names: Ad35-RSV-FA2; Ad35.RSV.FA2; JNJ-61187191; JNJ-61187191-AAA; Respiratory syncytial virus - CrucellLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Crucell
- Developer Crucell; Johnson & Johnson Innovative Medicine
- Class Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 May 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention, In volunteers) in USA (IM, Injection)
- 01 Sep 2016 Crucell Holland completes a phase I trial for Respiratory syncytial virus infections (Prevention, In volunteers) in USA (NCT02561871)